2023-05-31 13:19:46 ET
TD Cowen has initiated coverage of urology diagnostics maker MDxHealth ( NASDAQ: MDXH ) with an outperform rating, stating that it believes the current stock price "fails to reflect the company's progress or revenue/margin/cash flow opportunity ahead."
The investment bank noted that the stock was down around 44% year-to-date while its peers have risen about 20%, creating what it sees as "an attractive entry point."
TD Cowen said it sees a "credible" path to high-teen revenue growth with "significantly stronger" margins and positive free cash flow, "which we don't believe is reflected in the current valuation."
The bank's price target for the stock is $7.
More on medtech:
RBC Capital starts Nevro at outperform, views stock as undervalued
GE HealthCare to join the Nasdaq-100 Index
iRhythm receives FDA warning letter on California plant inspection
Morgan Stanley's top medtech picks are Medtronic, Alphatec, Becton Dickinson
For further details see:
TD Cowen starts MDxHealth at outperform, views stock as undervalued